Lv1
48 积分 2022-10-18 加入
Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models
11小时前
已完结
Challenges facing CAR T-cell immunotherapy in multiple myeloma
5天前
已完结
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
5天前
已完结
Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives
5天前
已完结
Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myeloma
5天前
已完结
Clinical Development of Bispecific Antibodies: Review, Advances, and Challenges in Hematological Malignancies
5天前
已完结
New BTK Inhibitors May Combat Resistance in CLL
10天前
已完结
A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions
11天前
已完结
Understanding the Molecular Mechanisms Underlying Anemia in Myelodysplastic Syndromes: From Erythropoiesis to New Therapeutic Approaches
11天前
已完结
MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms
11天前
已关闭
皖公网安备34019202002308
